Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
P/B ratio for Viridian Therapeutics, Inc. (VRDN)
P/B ratio as of 2023: 2.21
According to Viridian Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 2.21. At the end of 2022 the company had a P/B ratio of 2.37.
P/B ratio history for Viridian Therapeutics, Inc. from 2012 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 2.21 |
| 2022 | 2.37 |
| 2021 | 1.26 |
| 2020 | 0.49 |
| 2019 | 0.95 |
| 2018 | 1.75 |
| 2017 | 5.21 |
| 2016 | -166.30 |
| 2015 | 8.72 |
| 2014 | 14.35 |
| 2013 | 189.86 |
| 2012 | -17.75 |